What is the history of APLS stock?
Equity trading under the ticker symbol APLS reflects the corporate history and clinical development milestones of Apellis Pharmaceuticals, a commercial-stage biotechnology enterprise focused on complement immunotherapy. Founded to develop novel therapeutics for severe autoimmune and rare retinal diseases, the company's stock history has been driven by pivotal clinical trial results, regulatory drug approvals from health authorities, and subsequent commercialization phases for its breakthrough complement-inhibiting treatments across global healthcare markets.
Related FAQs
Nvidia Corporation possesses an exceptionally strong future growth outlook driven by its dominant market share in artificial intelligence computing, graphics processing units, and high-performance data center infrastructure.
In 2007, prior to its corporate name change from Research In Motion (RIM) and before the widespread market disruption caused by modern smartphones, BlackBerry stock experienced an explosive multi-year bull run.
The historical evolution of equity stocks and joint-stock companies began during the era of early European maritime exploration and mercantilism in the 17th century, most notably marked by the establishment of chartered trading enterprises like the D...
Apellis Pharmaceuticals (ticker APLS) attracts attention from biotechnology and healthcare equity investors following regulatory approvals and commercial launches of specialized therapies targeting rare retinal diseases.
Appili Therapeutics anticipates a progressive future as a specialty biopharmaceutical enterprise focused on developing anti-infective drug candidates addressing critical unmet medical needs in global public health.
Apellis Pharmaceuticals has reported a trailing twelve months revenue of approximately $1.
Yes, Bitdeer Technologies Group announced that it had sold its entire Bitcoin treasury, including reserves and weekly production, bringing its Bitcoin balance to zero as of February 20, 2026.
Equity research analysts covering Li Auto, trading under the ticker symbol LI, maintain mixed consensus recommendations reflecting intense price competition in China's electric vehicle market.
Aperam S.A. employs more than 13,000 professionals globally across its advanced stainless steel, specialty alloys, recycling, and renewable energy operations.
Apellis Pharmaceuticals, Inc.
Cedric Francois, holding the position of President and Chief Executive Officer at Apellis Pharmaceuticals, receives an extensive annual remuneration package valued at approximately $10.95 million.
Equity research analysts covering Apellis Pharmaceuticals, Inc. (APLS) maintain a favorable consensus rating, leaning predominantly toward strong buy and buy recommendations from major healthcare investment firms.
Employee reviews, workplace culture evaluations, and corporate feedback platforms indicate that Apellis Pharmaceuticals is generally regarded as a rewarding and progressive place to build a career within the biotechnology and biopharmaceutical sector...
Treatments developed and commercialized by Apellis Pharmaceuticals, such as specialized therapies for rare diseases, are generally subject to varying levels of coverage and prior authorization requirements by commercial health insurance providers and...